The results showed that the nivolumab group had a significantly higher overall survival (OS) rate compared to the placebo group (1-year: 27.3% vs 11.6%; 2-year: 10.6% vs 3.2%), and patients benefited regardless of their tumor’s PD-L1 expression (61). Here, CD274 is linked to neoplasm.